Get the Stockscreener App
3.30
1.54%
0.05
After Hours:
3.25
-0.05
-1.52%
Nrx Pharmaceuticals Inc stock is traded at $3.30, with a volume of 437.19K.
It is up +1.54% in the last 24 hours and up +42.24% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.25
Open:
$3.27
24h Volume:
437.19K
Relative Volume:
1.25
Market Cap:
$65.37M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.825
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
+15.79%
1M Performance:
+42.24%
6M Performance:
+60.98%
1Y Performance:
+95.27%
1-Day Range:
$3.20
$3.48
1-Week Range:
$2.83
$3.48
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.30 | 77.25M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Why NRx Pharmaceuticals Inc. Equity Warrant stock could outperform in 2025Quarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
NRx Pharmaceuticals (NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM) - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM) - The Globe and Mail
Quantitative breakdown of NRx Pharmaceuticals Inc. Equity Warrant recent moveTrade Ideas & Free Safe Entry Trade Signal Reports - newser.com
What Fibonacci levels say about NRx Pharmaceuticals Inc. reboundShort Setup & Daily Technical Forecast Reports - newser.com
Using flow based indicators on NRx Pharmaceuticals Inc.July 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Will NRx Pharmaceuticals Inc. stock gain from government policies2025 Key Lessons & High Accuracy Investment Signals - newser.com
NRx files ANDA for preservative-free ketamine amid US drug shortage - Investing.com Australia
Is NRx Pharmaceuticals Inc. stock safe for conservative investorsQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Is NRx Pharmaceuticals Inc. Equity Warrant forming a reversal pattern2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Does NRx Pharmaceuticals Inc. qualify in momentum factor screeningJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - newser.com
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - Great Falls Tribune
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion in 2034; - openPR.com
How to integrate NRx Pharmaceuticals Inc. into portfolio analysis tools2025 Analyst Calls & Growth Focused Entry Reports - newser.com
What Fibonacci levels say about NRx Pharmaceuticals Inc. Equity Warrant rebound2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
NRXP's Rating Maintained at 'Buy' by D. Boral Capital | NRXP Sto - GuruFocus
Can trapped investors hope for a rebound in NRx Pharmaceuticals Inc. Equity WarrantBond Market & Risk Controlled Swing Trade Alerts - newser.com
Visual trend scoring systems applied to NRx Pharmaceuticals Inc. Equity WarrantChart Signals & Community Trade Idea Sharing Platform - newser.com
Why NRx Pharmaceuticals Inc. Equity Warrant stock is seen as undervaluedQuarterly Investment Review & Daily Growth Stock Tips - newser.com
Nrx pharmaceuticals re-files anda for ketafree to fda - MarketScreener
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files - GlobeNewswire
$3.35B Market by 2034: NRx Develops Toxin-Free Ketamine as US Drug Shortage Continues - Stock Titan
Does NRx Pharmaceuticals Inc. show high probability of rebound2025 Retail Activity & Target Return Focused Stock Picks - newser.com
NRx Pharmaceuticals Inc Equity Warrant Stock Analysis and ForecastSupport and Resistance Levels & Small Budget Big Profits - earlytimes.in
Will NRx Pharmaceuticals Inc. Equity Warrant stock outperform international peers2025 Price Targets & Weekly Stock Breakout Alerts - newser.com
NRX Pharmaceuticals Gains FDA Approval for KETAFREE™ - MSN
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree - MSN
What to do if you’re stuck in NRx Pharmaceuticals Inc. Equity WarrantLayoff News & Verified Short-Term Plans - newser.com
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Joplin Globe
NRXP Stock Rating Maintained as 'Buy' by D. Boral Capital | NRXP - GuruFocus
NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital - MarketBeat
NRX Pharmaceuticals stock surges after FDA grants Suitability Petition By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product - Yahoo Finance
FDA Approval of Suitability Petition on Preservative-Free Ketamine Drug Supports $40 Analyst Target; $3 Billion Suicidal Depression Market: $NRXP - FinancialContent
NRx Pharmaceuticals Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine - citybiz
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product - The Globe and Mail
NRX Pharmaceuticals Gets FDA Approval of Suitability Petition for Preservative-Free Ketamine; Shares Rise - MarketScreener
Oklahoma City NewsThe Oklahoman - FinancialContent
NRX Pharmaceuticals stock surges after FDA grants Suitability Petition - Investing.com
Nrx Pharmaceuticals receives notification of US Food and Drug Administration approval of suitability petition - MarketScreener
NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - Investing News Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine - The Manila Times
NRx Pharmaceuticals Receives FDA Approval for Suitability Petition for KETAFREE™, Enabling Re-filing of ANDA for Preservative-Free Ketamine - Quiver Quantitative
Toxic-Free Ketamine Breakthrough: NRx Pharma Secures Critical FDA Approval for $750M Market Opportunity - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of "Buy" by Analysts - MarketBeat
NRx Pharmaceuticals advances relationship with Anson funds with $8.9M financing - MSN
Sectors Review: What is NRx Pharmaceuticals Incs revenue forecastJuly 2025 Reactions & Weekly Top Stock Performers List - khodrobank.com
Buyout Rumor: Is NRx Pharmaceuticals Inc. Equity Warrant likely to announce a buybackJuly 2025 Selloffs & Accurate Intraday Trading Signals - khodrobank.com
Swing Trade: What is NRx Pharmaceuticals Inc.’s book value per shareMarket Growth Report & Long-Term Safe Return Strategies - خودرو بانک
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):